Protecting Gross-to-Net Performance Through Single-Channel Ecosystems

Today’s guest post comes from Peter Darch, SVP of Strategy and Operations at PHIL Inc.

Peter explains that growing pressure on drug pricing is exposing structural inefficiencies in gross-to-net (GTN) across traditional distribution channels. He argues that single-channel ecosystems can better coordinate affordability, coverage, and dispensing, improving both patient outcomes and brand performance.

Click here to learn more about PHIL’s technology solution for brands.

Read on for Peter’s insights.

The Hidden Costs of Over-Customizing Your Hub Technology Stack

Today’s guest post comes from George Moore, Chief Product and Technology Officer at CareMetx.

George argues that customer relationship management (CRM) program customization delivers short-term workflow gains at the expense of long-term scalability, integration simplicity, and upgradeability. He highlights three common pitfalls and offers an approach on how to avoid them.

To learn more, download CareMetx’s Guide to Building an Agile, Scalable Hub Architecture.

Read on for George’s insights.

Where Gross-to-net Pressure Actually Lives After Launch

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Cindy explains that many gross-to-net (GTN) exposures now occur at the claim level, where evolving payer tactics, pharmacy economics, and copay complexity create unpredictable leakage. She argues that manufacturers must augment downstream review with real-time visibility and intervention to protect both revenue and patient access.

To learn more, register for ConnectiveRx’s free webinar on June 17: Gross-To-Net FOMO: What GTN Dangers Are You Missing Post-Launch?

Read on for Cindy’s insights.

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx.

Laura suggests that manufacturers must move beyond payer-centric models toward integrated, direct-to-consumer and employer channel strategies that connect pricing, demand, and fulfillment. She argues that this approach will help manufacturers convert patient intent into therapy initiation while expanding access at scale.

To learn more about GoodRx’s pharma solutions, visit GoodRx Pharma Direct.

Read on for Laura’s insights.

The Omnichannel Gap: Building the CRM of the Future for Patient Services

Today’s guest post comes from Karishma Desai, Associate Director of Data Strategy at Claritas Rx.

Karishma explains how the complexities of specialty therapies require a customer relationship management (CRM) system that unifies consent management. She goes on to explain that by embedding AI into the patient journey, automating workflows at scale, and enhancing collaboration among stakeholders, organizations can reduce delays, improve adherence, and deliver better patient outcomes.

To learn more, download Claritas Rx’s white paper: The Omnichannel Gap: Building the CRM of the Future for Patient Services.

Read on for Karishma's insights.

The Hidden Pitfalls of Hub Transitions—and How to Navigate Them

Today’s guest post comes from Brok Vandersteen, Vice President of Business Development at AssistRx.

Brok explains how missteps during patient support program transitions—ranging from service disruptions to data misalignment—can undermine access, adherence, and brand trust. He describes best practices organizations can use to ensure a smooth transition while protecting patients, providers, and program outcomes.

To learn more, download AssistRx’s Hub Transition Process Checklist. You can also schedule a meeting with the AssistRx team at the Asembia Summit in Las Vegas.

Read on for Brok’s insights.

Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26

Today’s guest post comes from Chrissy Hand, Chief Product and Commercial Officer at CoverMyMeds.

Chrissy highlights key themes in the future of patient access. She argues that policy changes, complex benefit designs, and affordability challenges require patient support services to be faster, more connected, and better aligned with real-world patient and provider needs.

Join CoverMyMeds’ April 23 AXS26 Innovation Roundtable.

Read on for Chrissy’s insights.

The Rare Journey Needs a Special Pharmacy Partner

Today’s guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.

Bansi argues that rare disease pharmacy is a fundamentally different model built around precision, speed, and hyper-personalized care. He suggests how manufacturers and stakeholders must rethink their assumptions to effectively support the unique demands of rare disease patient journeys.

Hear from PANTHERx patients and their caregivers about what it’s like to live each day with a rare disease.

Read on for Bansi’s insights.

Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand

Today’s guest post comes from Michael Harris, Vice President of Patient Support Services Strategy at Valeris.

Michael explores the rise of medical benefit maximizers as a new—and often overlooked—force shaping patient access. He outlines how these strategies can erode access, absorb support dollars, and introduce hidden risks for brands.

To learn more about Valeris’ technology solutions and data analytics capabilities, connect with Valeris.

Read on for Michael’s insights

Reshaping Patient Affordability: The Power of Expertise and Agility

Today’s guest post comes from Logan Melchione, Vice President of Patient Affordability at Paysign.

Logan examines how pharmaceutical manufacturers must rethink copay assistance in an era affected by maximizers, accumulators, and intensifying payer scrutiny. She argues that brands can both gain a strategic advantage and safeguard adherence by embracing claims-based precision, real-time adaptability, and transparent program design.

Request an analysis of your copay assistance program by emailing Paysign at affordability@paysign.com or by visiting paysign.com/rx.

Read on for Logan’s insights.

Time to Evolve: Hubs Flex to New Demands

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health.

Josh examines how hub models are evolving under mounting commercial, operational, and technological pressures. He argues that the next generation of patient services will be defined not by a single model, but by adaptability and shared strategy.

To learn more, download Cardinal Health’s latest hub evolution insights from its two-year trend archive: 2026 insourcing and outsourcing trends for patient hubs.

Read on for Josh’s insights.

Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences

Today’s guest post comes from Allison Bridges, SVP Client Success at PHIL Inc. and Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals

Allison and Cindy argue that many direct-to-patient (DTP) programs remain constrained by one-size-fits-all models that limit both patient experience and commercial performance. As patients increasingly expect convenience, choice, and price transparency, they suggest that manufacturers must evolve beyond static DTP channels toward more flexible, hybrid access models.

Click here to learn more about PHIL’s DTP 2.0 platform, PHIL Direct.

Read on for Allison and Cindy’s insights.

The State of Patient Access: What Industry Leaders Reveal in a New Survey About Hub Models, Technology, and the Road Ahead

Today’s guest post comes from Scott Genone, Chief Product Officer at CareMetx.

Scott shares findings from CareMetx’s 2026 Patient Services Report, based on a survey of more than 100 patient access decision-makers across biopharma, consulting, and specialty care. The results reveal an industry in transition. Hybrid hub models are becoming the norm, technology enablement remains uneven, and interoperability is emerging as a critical gating factor for meaningful progress.

To learn more, download CareMetx's 2026 Patient Services Report.

Read on for Scott’s insights.

In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward

Today’s guest post comes from Angie Franks, Chief Executive Officer at Kalderos.

Angie examines the growing uncertainty surrounding the 340B program and explains why comprehensive reform remains unlikely in the near term. She argues that claims-level transparency must serve as the foundation for a sustainable path forward. She describes Truzo, Kalderos’ solution for manufacturers and covered entities to work in real time to gain visibility into 340B drug discounts.

To learn more, schedule a meeting with the Kalderos legal team.

Read on for Angie’s insights.

From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026

Today’s guest post comes from Brok Vandersteen, Vice President of Business Development at AssistRx.

Brok argues that in 2026, traditional patient support program (PSP) models must evolve beyond task execution to deliver actionable insights, adaptive access strategies, and measurable ROI. He outlines four key considerations for transforming PSPs from cost centers into insight-driven engines of value.

To explore how life sciences organizations are rethinking patient support in 2026, download the AssistRx white paper: How Tech + Talent Delivers Patient Support Programs that Go Beyond the Call.

Read on for Brok’s insights.

New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Solutions at GoodRx.

Laura argues that patient self-pay has evolved from a temporary bridge to a core access strategy for new drug launches. She examines how manufacturer-funded self-pay offers can be operational from day one.

Click here to learn more about GoodRx’s access and affordability solutions.

Read on for Laura’s insights.

Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different

Today’s guest post is from Dr. Richard Faris, Chief Commercial and Clinical Officer at PANTHERx Rare.

Richard examines key considerations in launching rare disease therapies. He  argues that targeted reach, tighter relationships, and data-driven collaboration can improve success for both patients and manufacturers.

To learn more, download PANTHERx Rare's free guide: From PDUFA to Patient: A Guide to Rare Disease Launch Success.

Read on for Richard’s insights.

Closing the Specialty Access Gap: How GoodRx Turns Intent Into Therapy Starts

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Solutions at GoodRx

Laura explores the structural hurdles that slow time-to-therapy and outlines practical ways stakeholders can streamline the path from prescription intent to treatment initiation.

To learn more, book a meeting with GoodRx.

Read on for Laura’s insights.

The Hidden Burdens of Cancer Care: When Insurers Override Doctors

Today’s guest post comes from Josh Schwartz, Vice President, Medical Affairs, North America at BeOne Medicines and Matt Shaulis, General Manager, North America at BeOne Medicines.

Josh and Matt aim to raise awareness about the negative effects of insurer-imposed policies such as therapeutic substitution and step therapy. They argue that physicians have a deeper understanding of disease states and individual patient biology than insurance companies and pharmacy benefit managers (PBMs). To ensure the best outcomes, they contend that doctors—not insurers—should determine each patient’s optimal treatment plan.

Learn about BeOne Medicines, a global oncology company.

Read on for Josh and Matt’s insights.

The $700 Copay That Changed Everything

Today’s guest post comes from Stephen Hom, EVP, Chief Commercial Officer, and Co-Founder of RIS Rx.

Stephen argues that patient affordability remains one of the most critical—and often overlooked—barriers to treatment adherence. Drawing on his experience as a community pharmacist, he suggests that cost isn’t just a financial issue—it’s a clinical one.

To learn about RIS Rx’s Benefit Patient Solution (BPS) and other tools, request your savings snapshot.

Read on for Stephen’s insights.